Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialDavid J. Kuter, Janet L. Nichol, Louis M. Aledort et al.|The Lancet|2008Cited by 862
Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trialsJames N. George, Martin R. Schipperus, Susan D. Mathias et al.|British Journal of Haematology|2008Cited by 146
Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed <i>FLT3</i> Mutated AMLSelina M. Luger, Mark R. Litzow, Li Chen et al.|Blood|2024Cited by 7